NCT04102644 (LABOR) is a clinical trial of Observation in Birth Outcomes, sponsored by University of North Carolina, Chapel Hill.

Who is sponsoring NCT04102644?

NCT04102644 is sponsored by University of North Carolina, Chapel Hill.

What drugs are being tested in NCT04102644?

Interventions in NCT04102644: Observation.

What condition does NCT04102644 study?

NCT04102644 studies Birth Outcomes, Labor and Delivery, Respiratory Infection.

Is NCT04102644 still recruiting?

NCT04102644 is currently completed. Last updated 27 September 2022.

Last reviewed 2022-09-27 · How we verify

NCT04102644: LABOR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Limiting Adverse Birth Outcomes in Resource-Limited Settings

Completed Last updated 27 September 2022

What this trial tests

trial testing Observation in Birth Outcomes in 12,020 participants. Completed in 20 September 2022.

Timeline

31 October 2019

Primary endpoint
8 August 2022

20 September 2022

Quick facts

Lead sponsor	University of North Carolina, Chapel Hill
Status	Completed
Study type	OBSERVATIONAL
Enrollment	12,020
Start date	31 October 2019
Primary completion	8 August 2022
Estimated completion	20 September 2022
Sites	4 locations across Zambia, Ghana, India

Drugs / interventions tested

Observation

Conditions studied

Birth Outcomes — all drugs for Birth Outcomes →
Labor and Delivery — all drugs for Labor and Delivery →
Respiratory Infection — all drugs for Respiratory Infection →

Sponsor

University of North Carolina, Chapel Hill

Who can join

18 and older, any sex, with Birth Outcomes or Labor and Delivery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this research is to exhaustively document the course and outcomes of hospitalization, labor, delivery, and early postpartum course of up to 15,000 mother-newborn pairs in settings where the occurrence of adverse outcomes is high. The Investigators will gather detailed laboratory, physiologic, and clinical information, and precisely characterize major adverse diagnoses and outcomes. The resulting high-quality, granular, and generalizable data will be used to develop new algorithms to signal actionable intrapartum diagnoses and prospectively stratify women according to their risk for adverse maternal and neonatal outcomes.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Comprehensive pregnancy monitoring with a network of wireless, soft, and flexible sensors in high- and low-resource health settings.
Ryu D, Kim DH, Price JT, Lee JY, et al · · 2021 · cited 48× · PMID 33972445 · DOI 10.1073/pnas.2100466118
From lab to life: how wearable devices can improve health equity.
Walter JR, Xu S, Rogers JA. · · 2024 · cited 31× · PMID 38167483 · DOI 10.1038/s41467-023-44634-9
Limiting adverse birth outcomes in resource-limited settings (LABOR): protocol of a prospective intrapartum cohort study.
Adu-Amankwah A, Bellad MB, Benson AM, Beyuo TK, et al · · 2022 · cited 1× · PMID 36636742 · DOI 10.12688/gatesopenres.13716.2

Verify or expand the search:

Other trials of Observation

Trials testing the same drug.

NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
NCT07563088 — SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting
NCT07457099 — Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral a · not yet recruiting
NCT07472478 — Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12 · Phase 2 · not yet recruiting

Other recruiting trials for Birth Outcomes

Currently open trials in the same condition.

NCT07043647 — An Agricultural Livelihood Intervention for Pregnant Women · NA · recruiting
NCT06984614 — Effect of Snoezelen Room on Birth Process · NA · recruiting
NCT05935904 — Progression of Metabolic Syndrome Components During Pregnancy · recruiting

Other University of North Carolina, Chapel Hill trials

Trials by the same sponsor.

NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04102644 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
Last refreshed: 27 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04102644.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing